Histology Series 4: Improving The Reliability of NASH Clinical Trial Outcomes: What Is the Optimal Number of Hepatopathologists and Digital Slides, Pros and Cons
Materials
Agenda
Presentations
The Intercept ExperienceM. Michelle Berrey, Intercept Pharmaceuticals
Arun Sanyal, VCA
Hepatopathologist Survey and Histology SlidesElizabeth M. Brunt, Washington University School of Medicine in St. Louis
Lessons LearnedZachary Goodman, Inova Fairfax Hospital
Panel Discussion
Regulatory Guidance on NASH Data Specifications in Clinical Trials
.png)
